Using imaging and respiratory symptoms, researchers identified up to 15.4% of individuals without airflow obstruction as ...

Explore the future of the COPD market with our comprehensive report covering 68 geographic markets. Forecast drug sales growth from $17.4B in 2023 to $42.2B by 2033, driven by the US market. Gain ...

As monsoon arrives, respiratory ailments tend to spike due to humidity, sudden weather shifts, and increased allergens. For ...

Untreated COPD can lead to a faster progression of the disease, heart problems, and worsening respiratory infections. Keep reading to learn about the symptoms, causes, and how doctors treat COPD.

A new study highlights the Cardio-Ankle Vascular Index (CAVI) as a powerful tool for predicting COPD progression and outcomes ...

The US Food and Drug Administration (FDA) has approved mepolizumab as a maintenance treatment for chronic obstructive ...

Pharma group GSK has announced that US regulators have approved for use its Nucala treatment for adults with chronic ...

London: GSK plc has received approval from the US Food and Drug Administration (FDA) for Nucala (mepolizumab) as an add-on ...

A BMJ Open Respiratory Research study finds women aged over 40 face a 50% higher risk of developing COPD than men—even non-smokers. Indoor pollutants (cooking fumes, cleaning sprays), occupational ...

GSK’s Nucala receives US FDA approval for use in adults with chronic obstructive pulmonary disease: London, UK Saturday, May 24, 2025, 11:00 Hrs [IST] GSK plc announced that the ...

GSK has gained approval from the US Food and Drug Administration (FDA) for its monoclonal antibody, Nucala (mepolizumab), as ...

Skolnik said, “For example, pulmonary function tests like spirometry are very helpful in gaining insight as to whether ...